Literature DB >> 26926231

MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients.

O Landgren1, S Giralt2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26926231     DOI： 10.1038/bmt.2016.24

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

Authors:  Jesús F San Miguel; Julia Almeida; Gema Mateo; Joan Bladé; Consuelo López-Berges; Dolores Caballero; José Hernández; María Jesús Moro; Javier Fernández-Calvo; Joaquín Díaz-Mediavilla; Luis Palomera; Alberto Orfao
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

Review 2.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

3.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Authors:  Neha Korde; Mark Roschewski; Adriana Zingone; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Nishant Tageja; Dickran Kazandjian; Sham Mailankody; Peter Wu; Candis Morrison; Rene Costello; Yong Zhang; Debra Burton; Marcia Mulquin; Diamond Zuchlinski; Liz Lamping; Ashley Carpenter; Yvonne Wall; George Carter; Schuyler C Cunningham; Verena Gounden; Tristan M Sissung; Cody Peer; Irina Maric; Katherine R Calvo; Raul Braylan; Constance Yuan; Maryalice Stetler-Stevenson; Diane C Arthur; Katherine A Kong; Li Weng; Malek Faham; Liza Lindenberg; Karen Kurdziel; Peter Choyke; Seth M Steinberg; William Figg; Ola Landgren
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

Review 4.  Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Authors:  Sham Mailankody; Neha Korde; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

Review 5.  Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.

Authors:  Ola Landgren; Roger G Owen
Journal:  Cytometry B Clin Cytom       Date:  2015-12-22       Impact factor: 3.058

6.  Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Authors:  Andy C Rawstron; Faith E Davies; Ranjit DasGupta; A John Ashcroft; Russell Patmore; Mark T Drayson; Roger G Owen; Andrew S Jack; J Anthony Child; Gareth J Morgan
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

7.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Authors:  Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; María-José Terol; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Luis Palomera; Javier de la Rubia; Joaquín Díaz-Mediavilla; Anna Sureda; Ana Gorosquieta; Adrian Alegre; Alejandro Martin; Miguel T Hernández; Juan-José Lahuerta; Joan Bladé; Jesús F San Miguel
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

8.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.

Authors:  Bruno Paiva; Joaquin Martinez-Lopez; Maria-Belen Vidriales; Maria-Victoria Mateos; Maria-Angeles Montalban; Elena Fernandez-Redondo; Lourdes Alonso; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; José-Garcia Laraña; Enrique Bengoechea; Alejandro Martin; Joaquin Diaz Mediavilla; Luis Palomera; Felipe de Arriba; Joan Bladé; Alberto Orfao; Juan-Jose Lahuerta; Jesus F San Miguel
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

9.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

10.  Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Authors:  Andy C Rawstron; Walter M Gregory; Ruth M de Tute; Faith E Davies; Sue E Bell; Mark T Drayson; Gordon Cook; Graham H Jackson; Gareth J Morgan; J Anthony Child; Roger G Owen
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113
View more
  7 in total

Review 1.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

2.  Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!

Authors:  Ola Landgren; Dickran Kazandjian
Journal:  J Clin Oncol       Date:  2022-06-30       Impact factor: 50.717

3.  Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.

Authors:  Malin Hultcrantz; Even H Rustad; Venkata Yellapantula; Allison Jacob; Theresia Akhlaghi; Neha Korde; Sham Mailankody; Alexander M Lesokhin; Hani Hassoun; Eric L Smith; Oscar B Lahoud; Heather J Landau; Gunjan L Shah; Michael Scordo; David J Chung; Sergio Giralt; Elli Papaemmanuil; Ola Landgren
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

4.  Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

Authors:  Hervé Avet-Loiseau; Heinz Ludwig; Ola Landgren; Bruno Paiva; Chris Morris; Hui Yang; Kefei Zhou; Sunhee Ro; Maria-Victoria Mateos
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-09

Review 5.  The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?

Authors:  Dickran Kazandjian; Clifton C Mo; Ola Landgren; Paul G Richardson
Journal:  Br J Haematol       Date:  2020-06-05       Impact factor: 8.615

6.  Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.

Authors:  H Takamatsu; N Takezako; J Zheng; M Moorhead; V E H Carlton; K A Kong; R Murata; S Ito; T Miyamoto; K Yokoyama; K Matsue; T Sato; T Kurokawa; H Yagi; Y Terasaki; K Ohata; M Matsumoto; T Yoshida; M Faham; S Nakao
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 51.769

Review 7.  Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.

Authors:  Alessandro Gozzetti; Donatella Raspadori; Francesca Bacchiarri; Anna Sicuranza; Paola Pacelli; Ilaria Ferrigno; Dania Tocci; Monica Bocchia
Journal:  J Pers Med       Date:  2020-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.